Neuroendocrine Evaluation of Catecholaminergic Function in Man

Application to Research in Psychiatry and Neurology
  • S. Lal
  • N. P. V. Nair


Apomorphine (Apo), a dopamine (DA) receptor agonist in animals and man (Sourkes and Lal, 1975; Tsang and Lal, 1977; Lee et al., 1978), has been widely used in clinical research (Lal, 1981; Neumeyer et al., 1981) and has been the subject of several recent reviews (Sourkes and Lal, 1975; Colpaert et al., 1976; Di Chiara and Gessa, 1978). Apo and Clonidine, an α-adrenergic receptor agonist (Andén et al., 1970; Kobinger, 1978; Lovinger et al., 1976; Autret et al, 1977), increase growth hormone (GH) secretion (Lal et al., 1972a, 1973, 1975a; Brown et al., 1973). The GH response to these two agents provides a simple clinical approach to the study of DA and norepinephrine (NE) function in psychiatric and neurological disorders and to the investigation of the mode of action of psychoactive drugs and various treatment modalities in psychiatry (Lal and Nair, 1979; 1980; Lal et al., 1980a). The present chapter reviews some of the variables that affect Apo- and clonidine-induced GH secretion in normal subjects and points to the limitations as well as the application of this neuroendocrine approach in psychiatric and neurological research.


Growth Hormone Anorexia Nervosa Hepatic Encephalopathy Sleep Deprivation Essential Tremor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abrams, R. L., Grumbach, M. M., and Kaplan, S. L., 1971, The effect of administration of human growth hormone on the plasma growth hormone, Cortisol, glucose, and free fatty acid response to insulin: Evidence for growth hormone autoregulation in man, J. Clin. Invest. 50:940.PubMedCrossRefGoogle Scholar
  2. Andén, N.-E., Rubenson, A., Fuxe, K., and Hökfelt, T., 1967, Evidence for dopamine receptor stimulation by apomorphine, J. Pharm. Pharmacol. 19:627.PubMedCrossRefGoogle Scholar
  3. Andén, N.-E., Corrodi, H., Fuxe, K., Hökfelt, B., Hökfelt, T., Rydin, C., and Svensson, T., 1970, Evidence for a central noradrenaline receptor stimulation by Clonidine, Life Sci. 9:513.PubMedCrossRefGoogle Scholar
  4. Autret, A., Minz, M., Beillevaire, T., Cathala, H. P., and Schmitt, H., 1977, Effect of Clonidine on sleep patterns in man, Eur. J. Clin. Pharmacol. 12:319.PubMedCrossRefGoogle Scholar
  5. Balldin, J., 1981, Experimental and clinical studies on neuroendocrine and behavioural effects of electroconvulsive therapy, Reports from the Department of Psychiatry and Neurochemistry, St. Jorgen’s Hospital, University of Göteborg, No. 14, Gotab, Kungälv, Sweden.Google Scholar
  6. Balldin, J., Edén, S., Granérus, A.-K., Modigh, K., Svanborg, A., Walinder, J., and Wallin, L., 1980, Electroconvulsive therapy in Parkinson’s syndrome with on-off phenomenon, J. Neural Transm. 47:11.PubMedCrossRefGoogle Scholar
  7. Baxter, D. W., and Lal, S., 1979, Essential tremor and dystonic syndromes, Adv. Neurol. 24:373.Google Scholar
  8. Bloom, F. A., Segal, D., Ling, N., and Guillemin, R., 1976, Endorphins: Profound behavioral effects in rats suggest new etiological factors in mental illness, Science 194:630.PubMedCrossRefGoogle Scholar
  9. Brown, W. A., Van Woert, M. H., and Ambani, L. M., 1973, Effect of apomorphine on growth hormone release in humans, J. Clin. Endocrinol. Metab. 37:463.PubMedCrossRefGoogle Scholar
  10. Brown, W. A., Krieger, D. T., and Van Woert, M. H., 1974, Dissociation of growth hormone and Cortisol release following apomorphine, J. Clin. Endocrinol. Metab. 38:1127.PubMedCrossRefGoogle Scholar
  11. Bruyn, G. W., 1973, Neuropathological changes in Huntington’s chorea, Adv. Neurol. 1:399.Google Scholar
  12. Buchsbaum, M. S., Davis, G. C., and van Kämmen, D. P., 1980, Diagnostic classification and the endorphin hypothesis of schizophrenia: Individual differences and psychopharmacological strategies, in: Perspectives in Schizophrenia Research (C. Baxter and T. Melnechuk, eds.), pp. 177–194, Raven Press, New York.Google Scholar
  13. Bürki, H. R., Eichenberger, E., Sayers, A. C., and White, T. G., 1975, Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal, Pharmakopsychiatr. Neuro-psychopharmakol. 8:115.Google Scholar
  14. Casper, R. C., Davis, J. M., and Pandey, G. N., 1977, The effect of nutritional status and weight changes on hypothalamic function tests in anorexia nervosa, in: Anorexia Nervosa (R. A. Vigersky, ed.), pp. 137–147, Raven Press, New York.Google Scholar
  15. Cervantes, P., Lal, S., Smith, F., and Guyda, H., 1977, Dopaminergic function in two patients with catalepsy, Acta Psychiatr. Scand. 55:214.PubMedCrossRefGoogle Scholar
  16. Chiodini, P. G., Liuzzi, A., Botalla, G., Cremascoli, G., and Silvestrini, F., 1974, Inhibitory effect of dopaminergic stimulation on GH release in acromegaly, J. Clin. Endocrinol. Metab. 38:200.PubMedCrossRefGoogle Scholar
  17. Cole, J. O., and Gardos, G., 1980, Tardive dyskinesia, in: Psychopharmacology Update (J. O. Cole, ed.), pp. 151–164, Collamore Press, Lexington, Mass.Google Scholar
  18. Colpaert, F. C., Van Bever, W. F. M., and Leysen, J. E. M. F., 1976, Apomorphine: Chemistry, pharmacology, biochemistry, Int. Rev. Neurobiol. 19:225.PubMedCrossRefGoogle Scholar
  19. Cox, B., Ary, M., and Lomax, P., 1976, Changes in sensitivity to apomorphine during morphine dependence and withdrawal in rats, J. Pharmacol. Exp. Ther. 196:637.PubMedGoogle Scholar
  20. Davis, K. L., Hollister, L. E., Barchas, J. D., and Berger, P. A., 1976, Choline in tardive dyskinesia and Huntington’s chorea, Life Sci. 19:1507.PubMedCrossRefGoogle Scholar
  21. Di Chiara, G., and Gessa, G. L., 1978, Pharmacology and neurochemistry of apomorphine, Adv. Pharmacol. Chemother. 15:87.PubMedCrossRefGoogle Scholar
  22. Dudl, R. J., Ensinck, J. W., Palmer, H. E., and William, R. H., 1973, Effect of age on growth hormone secretion in man, J. Clin. Endocrinol. Metab. 37:11.CrossRefGoogle Scholar
  23. Ettigi, P., Lal, S., Martin, J. B., and Friesen, H. G., 1975, Effect of sex, oral contraceptives, and glucose loading on apomorphine-induced growth hormone secretion, J. Clin. Endocrinol. Metab. 40:1094.PubMedCrossRefGoogle Scholar
  24. Ettigi, P., Nair, N. P. V., Lal, S., Cervantes, P., and Guyda, H., 1976, Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with and without oral dyskinesia, withdrawn from chronic neuroleptic therapy, J. Neurol. Neurosurg. Psychiatry 39:870.PubMedCrossRefGoogle Scholar
  25. Fingerhut, M., and Krieger, D. T., 1974, Plasma growth hormone response to L-dopa in obese subjects, Metabolism 23:267.PubMedCrossRefGoogle Scholar
  26. Frantz, A. G., and Rabkin, M. T., 1965, Effects of estrogen and sex differences on secretion of human growth hormone, J. Clin. Endocrinol. Metab. 25:1470.PubMedCrossRefGoogle Scholar
  27. Frederiksen, P. K., 1975, Baclofen in the treatment of schizophrenia, Lancet 1:702.PubMedCrossRefGoogle Scholar
  28. Garver, D. L., Pandey, G. N., Hengeveld, C., and Davis, J. M., 1977, Growth hormone response and central aminergic systems in affective diseases, Psychopharmacol. Bull. 13:61.PubMedGoogle Scholar
  29. Gerner, R. H., Post, R. M., and Bunney, W. E., Jr., 1976, A dopaminergic mechanism in mania, Am. J. Psychiatry 133:1177.PubMedGoogle Scholar
  30. Gerner, R. H., Post, R. M., Gillin, J. C., and Bunney, W. E., Jr., 1979, Biological and behavioral effects of one night’s sleep deprivation in depressed patients and normals, J. Psychiatr. Res. 15:21.PubMedCrossRefGoogle Scholar
  31. Gruen, P. H., Sachar, E. J., Langer, G., Altman, N., Leifer, M., Frantz, A., and Halpern, F. S., 1978, Prolactin responses to neuroleptics in normal and schizophrenic subjects, Arch. Gen. Psychiatry 35:108.PubMedCrossRefGoogle Scholar
  32. Hartmann, E., Orzack, M. H., and Branconnier, P., 1977, Sleep deprivation deficits and their reversal by d- and l-amphetamine, Psychopharmacology 53:185.PubMedCrossRefGoogle Scholar
  33. Illig, R., and Prader, A., 1970, Effect of testosterone on growth hormone secretion in patients with anorchia and delayed puberty, J. Clin. Endocrinol. Metab. 30:615.CrossRefGoogle Scholar
  34. Kobinger, W., 1978, Central alpha-adrenergic systems as targets for hypotensive drugs, Rev. Physiol. Biochem. Pharmacol. 81:39.PubMedCrossRefGoogle Scholar
  35. Koulu, M., and Lammintausta, R., 1979, Effect of melatonin on L-tryptophan and apomorphine-stimulated growth hormone secretion in man, J. Clin. Endocrinol. Metab. 49:70.PubMedCrossRefGoogle Scholar
  36. Koulu, M., Lammintausta, R., and Dahlström, S., 1980, Effects of some gamma-aminobutyric acid (GABA)-ergic drugs on the dopaminergic control of human growth hormone secretion, J. Clin. Endocrinol. Metab. 51:124.PubMedCrossRefGoogle Scholar
  37. Lake, C. R., Sternberg, D. E., van Kämmen, D. P., Ballenger, J. C., Ziegler, M. G., Post, R. M., Kopin, I. J., and Bunney, W. E., Jr., 1980, Schizophrenia: Elevated cerebrospinal fluid norepinephrine, Science 207:331.PubMedCrossRefGoogle Scholar
  38. Lal, S., 1979, Pathophysiology and pharmacotherapy of spasmodic torticollis: A review, Can. J. Neurol. Sci. 6:427.PubMedGoogle Scholar
  39. Lal, S., 1981, Clinical studies with apomorphine, in: Clinical Pharmacology of Apomorphine and Other Dopaminomimetics, Vol. 2 (G. U. Corsini and G. L. Gessa, eds.), pp. 1–11, Raven Press, New York.Google Scholar
  40. Lal, S., and Martin, J. B., 1980, Neuroanatomy and neuropharmacological regulation of neuroendocrine function, in: Handbook of Biological Psychiatry, Vol. 3 (H. M. van Praag, M. H.Google Scholar
  41. Lader, O. J. Rafaelsen, and E. J. Sachar, eds.), pp. 101–167, Dekker, New York.Google Scholar
  42. Lal, S., and Nair, N. P. V., 1979, Growth hormone and prolactin responses in neuropsychiatrie research, Dev. Neurol. 2:179.Google Scholar
  43. Lal, S., and Nair, N.P.V., 1980, Effect of neuroleptics on prolactin and growth hormone secretion in man, Dev. Endocrinol. 9:223.Google Scholar
  44. Lal, S., and Rastogi, R. B., 1981, Effect of neuroleptics on pituitary function in man, in: Neuroendocrine Regulation and Altered Behavior (P. D. Hrdina and R. L. Singhal, eds.), pp. 169 – 183, Croom Helm, London.CrossRefGoogle Scholar
  45. Lal, S., de la Vega, C. E., Sourkes, T. L., and Friesen, H. G., 1972a, Effect of apomorphine on human growth hormone secretion, Lancet 11:661.CrossRefGoogle Scholar
  46. Lal, S., Sourkes, T. L., Missala, K., and Belendiuk, G., 1972b, Effects of aporphine and emetine alkaloids on central dopaminergic mechanisms in rats, Eurp. J. Pharmacol. 20:71.CrossRefGoogle Scholar
  47. Lal, S., de la Vega, C. E., Sourkes, T. L. and Friesen, H. G., 1973, Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum, J. Clin. Endocrinol. Metab. 37:719.PubMedCrossRefGoogle Scholar
  48. Lal, S., Aronoff, A., Garelis, E., Sourkes, T. L., Young, S. N., and de la Vega, C. E., 1974, Cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid, lactic acid, and pH before and after probenecid in hepatic coma, Clin. Neurol. Neurosurg. 77:142.CrossRefGoogle Scholar
  49. Lal, S., Tolis, G., Martin, J. B., Brown, G. M., and Guyda, H., 1975a, Effect of Clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone and thyroid stimulating hormone in the serum of normal men, J. Clin.Endocrinol. Metab. 41:827.PubMedCrossRefGoogle Scholar
  50. Lal, S., Martin, J. B., de la Vega, C. E., and Friesen, H. G., 1975b, Comparison of the effect of apomorphine and L-dopa on serum growth hormone levels in normal men, Clin. Endocrinol. 4:277.CrossRefGoogle Scholar
  51. Lal, S., Guyda, H., and Bikadoroff, S., 1977, Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men, J. Clin. Endocrinol. Metab. 44:766.PubMedCrossRefGoogle Scholar
  52. Lal, S., Nair, N. P. V., and Guyda, H., 1978, The effect of lithium on hypothalamic-pituitary dopaminergic function, Acta Psychiatr. Scand. 57:91.PubMedCrossRefGoogle Scholar
  53. Lal, S., Nair, N. P. V., Cervantes, P., Pulman, J., and Guyda, H., 1979a, Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion, Acta Psychiatr. Scand. 59:173.PubMedCrossRefGoogle Scholar
  54. Lal, S., Mendis, T., Cervantes, P., Guyda, H., and De Rivera, J. L., 1979b, Effect of benztropine on haloperidol-induced prolactin secretion, Neuropsychobiology 5:327.PubMedCrossRefGoogle Scholar
  55. Lal, S., Hoyte, K., Kiely, M. E., Sourkes, T. L., Baxter, D. W., Missala, K., and Andermann, F., 1979c, Neuropharmacological investigation and treatment of spasmodic torticollis, Adv. Neurol. 24:335.Google Scholar
  56. Lal, S., Nair, N. P. V., Cervantes, P., and Guyda, H., 1980a, Use of drug-induced growth hormone and prolactin responses in psychiatric research, in: Progress in Psychoneuroendocrinology (F. Brambilla, G. Racagni, and D. de Wied, eds.), pp. 295–307, Elsevier/North-Holland, Amsterdam.Google Scholar
  57. Lal, S., Young, S. N., Cervantes, P., and Guyda, H., 1980b, Effect of L-tryptophan on apomorphine-induced growth hormone secretion in normal subjects, Pharmakopsychiatr. Neuro-Psychopharmakol. 13:331.Google Scholar
  58. Lal, S., Cervantes, P., and Nair, N. P. V., 1980c, Failure of naloxone to reverse catalepsy associated with schizophrenia: A case report, Psychiatr. J. Univ. Ottawa 5:160.Google Scholar
  59. Lal, S., Etienne, P., Thavundayil, J., Nair, N. P. V., Collier, B., Rastogi, R., Guyda, H., and Schwartz, G., 1981a, Effect of choline on central dopaminergic function in normal subjects, J. Neural Transm. 50:29.PubMedCrossRefGoogle Scholar
  60. Lal, S., Thavundayil, J., Nair, N. P. V., Etienne, P., Rastogi, R., Schwartz, G., Pulman, J., and Guyda, H., 1981b, Effect of sleep deprivation on dopamine receptor function in normal subjects, J. Neural Transm. 50:39.PubMedCrossRefGoogle Scholar
  61. Lal, S., Oravec, M., Aronoff, A., Kiely, M. E., Guyda, H., Solomon, S., and Nair, N. P. V., 1981c, Hypothalamic-pituitary dopaminergic function in hepatic failure in man, J. Neural Transm. 53:7.CrossRefGoogle Scholar
  62. Lal, S., Tolis, G., McDonald, T. J., Cervantes, P., and Dupré, J., 1981d, Effect of Clonidine on growth hormone and glucagon secretion, Horm. Metab. Res. 13:648.PubMedCrossRefGoogle Scholar
  63. Langer, G., Heinze, B., Reim, B., and Matussek, N., 1976, Reduced growth hormone responses to amphetamine in “endogenous” depressive patients: Studies in normal, “reactive” and “endogenous” depressive, schizophrenic, and chronic alcoholic subjects, Arch. Gen. Psychiatry 33:1471.PubMedCrossRefGoogle Scholar
  64. Langston, J. W., and Forno, L. S., 1978, The hypothalamus in Parkinson disease, Ann. Neurol. 3:129.PubMedCrossRefGoogle Scholar
  65. Lee, T., Seeman, P., Tourtellotte, W. W., Farley, I. J., and Hornykiewicz, O., 1978, Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains, Nature (London) 274:897.CrossRefGoogle Scholar
  66. Levy, C. H., Carlson, H. E., Sowers, J. R., Goodlett, R. E., Tourtellotte, W. W., and Hershman, J. M., 1979, Growth hormone and prolactin secretion in Huntington’s disease, Life Sci. 24:743.PubMedCrossRefGoogle Scholar
  67. Linnoila, M., Viukari, M., and Hietala, O., 1976, Effect of sodium valproate on tardive dyskinesia, Br. J. Psychiatry 129:114.PubMedCrossRefGoogle Scholar
  68. Lorenzi, M., Tsalikian, E., Bohannon, N. V., Gerich, J. E., Karam, J. H., and Forsham, P. H., 1977, Differential effects of L-dopa and apomorphine on glucagon secretion in man: Evidence against central dopaminergic stimulation of glucagon, J. Clin. Endocrinol. Metab. 45:1154.PubMedCrossRefGoogle Scholar
  69. Lovinger, R., Holland, J., Kaplan, S., Grumbach, M., Boryczka, A. T., Shackleford, R., Salmon, J., Reid, I. A., and Ganong, W. F., 1976, Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs, Neuroscience 1:443.PubMedCrossRefGoogle Scholar
  70. Maany, I., Frazer, A., and Mendels, J., 1975, Apomorphine: Effect on growth hormone, J. Clin. Endocrinol. Metab. 40:162.PubMedCrossRefGoogle Scholar
  71. Maany, I., Mendels, J., Frazer, A., and Brunswick, D., 1979, A study of growth hormone release in depression, Neuropsychobiology 5:282.PubMedCrossRefGoogle Scholar
  72. Malick, J. B., Millingsley, M. L., Kubena, R. K., and Goldstein, J. M., 1977, Evaluation of naloxone in laboratory tests predictive of clinical antipsychotic activity, Commun. Psychopharmacol. 1:475.PubMedGoogle Scholar
  73. Martin, J. B., Lal, S., Tolis, G., and Friesen, H. G., 1974, Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin, J. Clin. Endocrinol. Metab. 39:180.PubMedCrossRefGoogle Scholar
  74. Martin, L. G., Clark, J. W., and Connor, T. B., 1968, Growth hormone secretion enhanced by androgens, J. Clin. Endocrinol. Metab. 28:425.PubMedCrossRefGoogle Scholar
  75. Matussek, N., 1978, Effect of amphetamine and Clonidine on human growth hormone release in psychiatric patients and controls, in: Depressive Disorders (S. Garattini, ed.), pp. 431–446, Schattauer Verlag, Stuttgart.Google Scholar
  76. Matussek, N., Ackenheil, M., Hippius, H., Muller, F., Schröeder, H. T., Schultes, H., and Wasilewski, B., 1980, Effect of Clonidine on growth hormone release in psychiatric patients and controls, Psychiatry Res. 2:25.PubMedCrossRefGoogle Scholar
  77. Meltzer, H. Y., and Stahl, S. M., 1976, The dopamine hypothesis of schizophrenia: A review, Schizophr. Bull. 2:19.PubMedGoogle Scholar
  78. Meltzer, H. Y., Busch, D., So, R., Holcomb, H., and Fang, V. S., 1980, Neuroleptic-induced elevations in serum prolactin levels: Etiology and significance, in: Perspectives in Schizophrenia Research (C. Baxter and T. Melnechuk, eds.), pp. 149–176, Raven Press, New York.Google Scholar
  79. Merimee, T. J., and Fineberg, S. E., 1971, Studies of the sex based variation of human growth hormone secretion, J. Clin. Endocrinol. Metab. 33:896.PubMedCrossRefGoogle Scholar
  80. Merimee, T. J., Burgess, J. A., and Rabinowitz, D., 1966, Sex determined variation in serum insulin and growth hormone response to amino acid stimulation, J. Clin. Endocrinol. Metab. 26:791.CrossRefGoogle Scholar
  81. Mims, R. B., Scott, C. L., Modebe, O. M., and Bethune, J. E., 1973, Prevention of L-dopa-induced growth hormone stimulation by hyperglycemia, J. Clin. Endocrinol. Metab. 37:660.PubMedCrossRefGoogle Scholar
  82. Modigh, K., Balldin, J., Edén, S., Granérus, A.-K., and Walinder, J., 1981, Electroconvulsive therapy and receptor sensitivity, Acta Psychiatr. Scand. (Suppl. 290) 63:91.Google Scholar
  83. Morgan, M. Y., Jakobovits, A. W., James, I. M., and Sherlock, S., 1980, Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy, Gastroenterology 78:663.PubMedGoogle Scholar
  84. Müller, E. E., Parati, E. A., Cocchi, D., Zanardi, P., and Caraceni, T., 1979, Dopaminergic drugs on growth hormone and prolactin secretion in Huntington’s disease, Adv. Neurol. 23:319.Google Scholar
  85. Nair, N. P. V., Zickerman, V., and Schwartz, G., 1977, Dopamine and schizophrenia: A reappraisal in the light of clinical studies with clozapine, Can. Psychiatr. Assoc. J. 22:285.PubMedGoogle Scholar
  86. Nair, N. P. V., Yassa, R., Ruiz-Navarro, J., and Schwartz, G., 1978, Baclofen in the treatment of tardive dyskinesia, Am. J. Psychiatry 135:1562.PubMedGoogle Scholar
  87. Nair, N. P. V., Lal, S., Cervantes, P., Yassa, R., and Guyda, H., 1979, Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia, Neuropsychobiology 5:136.PubMedCrossRefGoogle Scholar
  88. Nair, N. P. V., Lal, S., and Guyda, H., 1980, Effects of GABA-ergic drugs on nigrostriatal and hypothalamic-pituitary dopaminergic systems, Brain Res. Bull. 5(Suppl. 2):427.CrossRefGoogle Scholar
  89. Neumeyer, J. L., Lal, S., and Baldessarini, R. J., 1981, Historical highlights of the chemistry, pharmacology and early clinical uses of apomorphine, in: Clinical Pharmacology of Apomorphine and other Dopaminomimetics Vol. 1 (G. U. Corsini and G. L. Gessa, eds.), pp. 1–18, Raven Press, New York.Google Scholar
  90. Nilsson, K. O., 1975, Lack of effect of hyperglycaemia on apomorphine-induced growth hormone release in normal man, Acta Endocrinol. (Kbh.) 80:230.Google Scholar
  91. Pandey, G. N., Garver, D. L., Tamminga, C., Erickson, S., Ali, S. I., and Davis, J. M., 1977, Postsynaptic supersensitivity in schizophrenia, Am. J. Psychiatry 134:518.PubMedGoogle Scholar
  92. Papavasiliou, P. S., and Rosal, V., 1979, Effects of choline in patients with levodopa-induced dyskinesia, Nutr. Brain 5:335.Google Scholar
  93. Papeschi, R., 1972, Dopamine, extrapyramidal system and psychomotor function, Psychiatr. Neurol. Neurochir. 75:13.PubMedGoogle Scholar
  94. Papeschi, R., Randrup, A., and Lal, S., 1974, Effect of ECT on dopaminergic and noradrenergic mechanisms. I. Effect on the behavioral changes induced by reserpine, alpha-methyl-p-tyrosine or amphetamine, Psychopharmacologia 35:149.PubMedCrossRefGoogle Scholar
  95. Pert, A., Rosenblatt, J. E., Sivit, C., Pert, C. B., and Bunney, W. E., Jr., 1978, Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity, Science 201:171.PubMedCrossRefGoogle Scholar
  96. Powers, P., Douglass, T. S., and Waziri, R., 1976, Hyperpyrexia in catatonic states, Dis. Nerv. Syst. 37:359.PubMedGoogle Scholar
  97. Rao, A., 1964, A controlled trial with “valium” in some psychiatric disorders, Indian J. Psychiatry 6:188.Google Scholar
  98. Rotrosen, J., Angrist, B., Gershon, S., Paquin, J., Branchey, L., Oleshansky, M., Halpern, F., and Sachar, E. J., 1979, Neuroendocrine effects of apomorphine: Characterization of response patterns and application to schizophrenia research, Br. J. Psychiatry 135:444.PubMedCrossRefGoogle Scholar
  99. Sachar, E. J., Altman, N., Gruen, P. H., Glassman, A., Halpern, F. S., and Sassin, J., 1975, Human growth hormone response to levodopa: Relation to menopause, depression, and plasma dopa concentration, Arch. Gen. Psychiatry 32:502.PubMedCrossRefGoogle Scholar
  100. Sahakian, B. J., Wurtman, R. J., Barr, J. K., Millington, W. R., and Chiel, H. J., 1979, Low tryptophan diet decreases brain serotonin and alters response to apomorphine, Nature (London) 279:731.CrossRefGoogle Scholar
  101. Schorderet, M., 1977, Lithium-inhibition of cyclic AMP accumulation induced by dopamine in isolated retinae of the rabbit, Biochem. Pharmacol. 26:167.PubMedCrossRefGoogle Scholar
  102. Sherman, B. M., and Halmi, K. A., 1977, Effect of nutritional rehabilitation on hypothalamic-pituitary function in anorexia nervosa, in: Anorexia Nervosa (R. A. Vigersky, ed.), pp. 211–224, Raven Press, New York.Google Scholar
  103. Snyder, S. H., Banerjee, S. P., Yamamura, H. I., and Greenberg, D., 1974, Drugs, neurotransmitters, and schizophrenia: Phenothiazines, amphetamines, and enzymes synthesizing psychomimetic drugs aid schizophrenia research, Science 184:1243.PubMedCrossRefGoogle Scholar
  104. Sourkes, T. L., and Lal, S., 1975, Apomorphine and its relation to dopamine in the nervous system, Adv. Neurochem. 1:247.Google Scholar
  105. Stjernholm, M. R., Alsever, R. N., and Beck, P., 1975, Growth hormone release after synthetic 1–24 ACTH: Effects of estrogen and sex, J. Clin. Endocrinol. Metab. 40:516.PubMedCrossRefGoogle Scholar
  106. Stock, G., Magnusson, T., and Andén, N.-E, 1973, Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow, Nau-nyn-Schmiedebergs Arch. Pharmakol. 278:347.CrossRefGoogle Scholar
  107. Symes, A. L., Lal, S., and Sourkes, T. L., 1976, Time-course of apomorphine in the brain of the immature rat after apomorphine injection, Arch. Int. Pharmacodyn. Ther. 223:260.PubMedGoogle Scholar
  108. Symes, A. L., Lal, S., Young, S. N., Tsang, D., and Sourkes, T. L., 1977, Effect of chronic chlorpromazine administration or prior treatment with reserpine on brain apomorphine concentrations and apomorphine-induced stereotyped behaviour in the rat, Eur. J. Pharmacol. 43:173.PubMedCrossRefGoogle Scholar
  109. Tamminga, C. A., Smith, R. C., Pandey, G., Frohman, L. A., and Davis, J. M., 1977, A neuroendocrine study of supersensitivity in tardive dyskinesia, Arch. Gen. Psychiatry 34:1119.CrossRefGoogle Scholar
  110. Tarsy, D., and Baldessarini, R. J., 1977, The pathophysiologic basis of tardive dyskinesia, Biol. Psychiatry 12:431.PubMedGoogle Scholar
  111. Tolis, G., Lal, S., and Pinter, E., 1975, Reduced growth hormone responses to apomorphine and L-dopa in obesity, in: Symposium of the International Society of Psychoendocrinology, pp. 335–339, Publishing House of the Hungarian Academy of Sciences, Viségrad.Google Scholar
  112. Tsang, D., and Lal, S., 1977, Effect of monoamine receptor agonists and antagonists on cyclic AMP accumulation in human cerebral cortex slices, Can. J. Physiol. Pharmacol. 55:1263.PubMedCrossRefGoogle Scholar
  113. Tufik, S., Lindsey, C. J., and Carlini, E. A., 1978, Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain?, Pharmacology 16:98.PubMedCrossRefGoogle Scholar
  114. Tulandi, T., Mclnnes, R. A., Mehta, A., and Tolis, G., 1981, Pseudocyesis: Pituitary function before and after resolution of symptoms, Obstet. Gynecol. 59:119.Google Scholar
  115. van Kammen, D. P., and Murphy, D. L., 1975, Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment, Psychopharmacologia 44:215.PubMedCrossRefGoogle Scholar
  116. Van Tyle, W. K., and Burkman, A. M., 1971, Spectrofluorometric assay of apomorphine in brain tissue, J. Pharm. Sci. 60:1736.PubMedCrossRefGoogle Scholar
  117. Young, S. N., Lal, S., Feldmuller, F., Sourkes, T. L., Ford, R. M., Kiely, M., and Martin, J. B., 1976, Parallel variation of ventricular CSF tryptophan and free serum tryptophan in man, J. Neurol. Neurosurg. Psychiatry 39:61.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • S. Lal
    • 1
    • 2
  • N. P. V. Nair
    • 3
  1. 1.Douglas Hospital Research Centre, Department of PsychiatryMontreal General HospitalMontrealCanada
  2. 2.Department of PsychiatryMcGill UniversityMontrealCanada
  3. 3.Douglas Hospital Research Centre, and Department of PsychiatryMcGill UniversityMontrealCanada

Personalised recommendations